Literature DB >> 28011104

Microwave ablation of renal tumors: A narrative review of technical considerations and clinical results.

F H Cornelis1, C Marcelin2, J-C Bernhard3.   

Abstract

PURPOSE: The purpose of this review was to identify the specific technical considerations to adequately perform microwave ablations (MWA) of renal tumors and analyze the currently available clinical results.
METHODS: Using Medline, a systematic review was performed including articles published between January 2000 and September 2016. English language original articles, reviews and editorials were selected based on their clinical relevance.
RESULTS: MWA has several theoretical advantages over radiofrequency ablation in consistently providing higher intratumoral temperatures. MWA is less dependent of electrical conductivities of tissues and the delivered energy is less limited by desiccation of heated tissues. While there are insufficient data, especially because of a lack of studies with mid- to long-term follow-up, to determine the oncologic effectiveness of MWA, this technique appears safe and effective for the ablation of T1 renal tumors. There is evidence for using mid-level settings based on experimental and clinical data. Power set at 50-65W for 5-15min appears adequate in kidney but close clinical and imaging follow-up have to be performed.
CONCLUSION: Renal MWA offers theoretical advantages by comparison with other available techniques to treat renal tumors. However, MWA suffers of less cumulative data compared to radiofrequency ablation or cryoablation. Moreover, microwaves still require further studies to identify the optimal tumor characteristics and device settings leading to predictable ablation.
Copyright © 2016 Éditions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Interventional imaging; Kidney; Microwave ablation; Renal ablation; Renal cancer

Mesh:

Year:  2016        PMID: 28011104     DOI: 10.1016/j.diii.2016.12.002

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  6 in total

1.  Urologic and interventional radiology treatment of renal cell carcinomas-similarities and differences.

Authors:  Diep Nguyen; Eric vanSonnenberg; Paul Kang; Peter R Mueller
Journal:  Ann Transl Med       Date:  2019-07

2.  Safety and efficacy of RFA versus MWA for T1a renal cell carcinoma: a propensity score analysis.

Authors:  Brigit M Aarts; Fernando M Gomez; Marta Lopez-Yurda; Rob F M Bevers; Joris Herndriks; Regina G H Beets-Tan; Axel Bex; Elisabeth G Klompenhouwer; Rutger W van der Meer
Journal:  Eur Radiol       Date:  2022-09-06       Impact factor: 7.034

Review 3.  Tips and tricks for a safe and effective image-guided percutaneous renal tumour ablation.

Authors:  Giovanni Mauri; L Nicosia; G M Varano; G Bonomo; P Della Vigna; L Monfardini; F Orsi
Journal:  Insights Imaging       Date:  2017-05-12

4.  Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell Carcinoma.

Authors:  B M Aarts; W Prevoo; M A J Meier; A Bex; R G H Beets-Tan; E G Klompenhouwer; F M Gómez
Journal:  Cardiovasc Intervent Radiol       Date:  2020-02-12       Impact factor: 2.740

5.  A multicenter 10-year oncologic outcome of ultrasound-guided percutaneous microwave ablation of clinical T1 renal cell carcinoma: will it stand the test of time?

Authors:  Jie Yu; Hui Wang; Zhi-Gang Cheng; Fang-Yi Liu; Qin-Ying Li; Guang-Zhi He; Yan-Chun Luo; Xiao-Ling Yu; Zhi-Yu Han; Ping Liang
Journal:  Eur Radiol       Date:  2021-06-30       Impact factor: 5.315

6.  Use of microwave ablation in the treatment of patients with multiple primary malignant tumors.

Authors:  Yue Han; Na Shao; Xiaoming Xi; Xuezhi Hao
Journal:  Thorac Cancer       Date:  2017-05-31       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.